Last reviewed · How we verify
HS-10384 tablets
At a glance
| Generic name | HS-10384 tablets |
|---|---|
| Sponsor | Hansoh BioMedical R&D Company |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Study to Find the Best Dose of HS-10384 to Treat Vasomotor Symptoms in Postmenopausal Women (PHASE2)
- Study of HS-10384 in Participants of Chinese Postmenopausal Women (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- HS-10384 tablets CI brief — competitive landscape report
- HS-10384 tablets updates RSS · CI watch RSS
- Hansoh BioMedical R&D Company portfolio CI